1. Home
  2. MDGL vs DTM Comparison

MDGL vs DTM Comparison

Compare MDGL & DTM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • MDGL
  • DTM
  • Stock Information
  • Founded
  • MDGL 2011
  • DTM 2021
  • Country
  • MDGL United States
  • DTM United States
  • Employees
  • MDGL N/A
  • DTM N/A
  • Industry
  • MDGL Biotechnology: Pharmaceutical Preparations
  • DTM Oil & Gas Production
  • Sector
  • MDGL Health Care
  • DTM Utilities
  • Exchange
  • MDGL Nasdaq
  • DTM Nasdaq
  • Market Cap
  • MDGL 9.6B
  • DTM 11.1B
  • IPO Year
  • MDGL N/A
  • DTM N/A
  • Fundamental
  • Price
  • MDGL $530.11
  • DTM $115.40
  • Analyst Decision
  • MDGL Strong Buy
  • DTM Buy
  • Analyst Count
  • MDGL 13
  • DTM 12
  • Target Price
  • MDGL $523.92
  • DTM $118.08
  • AVG Volume (30 Days)
  • MDGL 409.9K
  • DTM 804.5K
  • Earning Date
  • MDGL 11-04-2025
  • DTM 10-30-2025
  • Dividend Yield
  • MDGL N/A
  • DTM 2.84%
  • EPS Growth
  • MDGL N/A
  • DTM N/A
  • EPS
  • MDGL N/A
  • DTM 3.96
  • Revenue
  • MDGL $740,640,000.00
  • DTM $1,175,000,000.00
  • Revenue This Year
  • MDGL $395.75
  • DTM $27.01
  • Revenue Next Year
  • MDGL $65.73
  • DTM $8.91
  • P/E Ratio
  • MDGL N/A
  • DTM $29.16
  • Revenue Growth
  • MDGL 864.21
  • DTM 20.39
  • 52 Week Low
  • MDGL $265.00
  • DTM $83.30
  • 52 Week High
  • MDGL $544.25
  • DTM $115.80
  • Technical
  • Relative Strength Index (RSI)
  • MDGL 74.00
  • DTM 65.70
  • Support Level
  • MDGL $399.00
  • DTM $109.12
  • Resistance Level
  • MDGL $544.25
  • DTM $115.58
  • Average True Range (ATR)
  • MDGL 27.05
  • DTM 2.47
  • MACD
  • MDGL 11.07
  • DTM 0.73
  • Stochastic Oscillator
  • MDGL 91.20
  • DTM 96.99

About MDGL Madrigal Pharmaceuticals Inc.

Madrigal Pharmaceuticals Inc is a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), a serious liver disease with high unmet medical need that can lead to cirrhosis, liver failure, and premature mortality. The company's medication, Rezdiffra (resmetirom), is a once-daily, oral, liver-directed thyroid hormone receptor agonist designed to target key underlying causes of MASH.

About DTM DT Midstream Inc.

DT Midstream Inc is an owner, operator, and developer of natural gas midstream interstate and intrastate pipelines; storage and gathering systems; and compression, treatment, and surface facilities. It provides multiple, integrated natural gas services to customers through interstate pipelines, intrastate pipelines, storage systems, lateral pipelines and related treatment plants and compression and surface facilities, and gathering systems and related treatment plants and compression and surface facilities. The segments of the group are Pipeline and Gathering. It generates revenue from pipeline, storage, and gathering systems, substantially all of which are located in the Midwestern U.S., Eastern Canada, Northeastern U.S., and Gulf Coast regions.

Share on Social Networks: